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OBJECTIVES: Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia. The 
prevalence among adults is estimated to be q1% in Sweden, increasing with age to 
nearly 10% among those over 80. The proportion of elderly will rise in coming years 
resulting in a higher prevalence of AF and probably increasing costs to the Swedish 
society. The aim of the present study was to estimate the annual cost of AF from a 
Swedish perspective. In addition, validity of data and problems regarding diagnosis 
coding were evaluated. METHODS: Prevalence-based cost-of-illness analysis of AF 
based on year 2007. Direct medical and non-medical, as well as indirect costs, were 
considered. Data were based on information from the literature, Swedish registries, 
and an expert panel. RESULTS: The annual total cost of AF was estimated to be 
SEK6600 million (approximately a600 million); direct medical costs 84%, direct non-
medical costs 4%, and indirect costs 12%. The key driver (55%) of the result was the 
direct cost of heart failure and stroke, both having developed as a consequence of AF. 
Data from the registries were somewhat difﬁcult to interpret due to possible miscoding 
or ambiguity in data inputs. In particular there was uncertainty associated with the 
coding of primary and secondary diagnosis as the cause-and-effect relationship varies 
between patients. CONCLUSIONS: This is the ﬁrst comprehensive analysis of the 
direct and indirect costs of AF and its main complications in Sweden. The results 
showed the annual cost of AF is very high, but it is still likely to be underestimated 
as a conservative approach was applied in the analysis. This suggests further research 
is needed.
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OBJECTIVES: Estimate annual direct costs for privately-insured US chronic throm-
boembolic pulmonary hypertension (CTEPH) patients and matched controls. 
METHODS: From a privately-insured claims database (8 million beneﬁciaries, 
2002–2007), 423 CTEPH patients were identiﬁed as having: q2 claims for pulmonary 
hypertension (ICD-9: 416.0, 416.8); q1 claim for pulmonary embolism (ICD-9: 415.1,       
V12.51; ICD-9 procedure: 38.7; CPT-4: 36010, 37620, 75825, 75940; HCPCS: 
C1880) within 12 months prior or 1 month after the initial pulmonary hypertension 
claim (index date); ages 18–64. Patients with CTEPH were matched demographically 
to controls without pulmonary hypertension. All were required to have continuous 
coverage for 6 months before (baseline) and 1 month after index date. A variable 
study period was used to follow patients as long as continuously elgible; mean follow-
up was 20.5 months. Chi-squared tests were used to compare baseline comorbidities. 
Wilcoxon rank-sum tests were used for univariate comparisons of direct (medical and 
pharmaceutical) patient-month costs to insurers for CTEPH patients vs. controls. 
RESULTS: Average age for patients with CTEPH was 52.4 years, and 58.20% were 
women. Compared with controls, CTEPH patients had signiﬁcantly higher baseline 
comorbidity rates (e.g., essential hypertension, congestive heart failure, chronic pul-
monary disease, and diabetes) and a higher Charlson Comorbidity Index. Mean 
(median) direct patient-month costs were $4456 ($1305) for CTEPH patients and 
$457 ($90) for controls (p  0.0001), yielding excess costs of $8441 ($215). Inpatient 
services accounted for 53%, outpatient services for 33%, and drug costs for 12% of 
CTEPH patient-month direct costs. Circulatory/respiratory system-related patient-
month costs were $2289 ($617) among CTEPH patients and $110 ($7) among con-
trols (p  0.0001), yielding excess costs of $2179 ($5610). CONCLUSIONS: Patients 
with CTEPH had substantially higher costs than matched controls. Circulatory/respi-
ratory system-related costs represented 51% of the costs of patients with CTEPH and 
54% of the difference in costs between patients with CTEPH and controls.
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OBJECTIVES: Atrial ﬁbrillation (AF), the most common cardiac arrhythmia, is 
strongly associated with increased risk of stroke and thromboembolism. AF prevalence 
increases with age. In many countries there is a growing awareness of the economic 
burden associated with AF in light of ageing populations and constrained public 
ﬁnances. This study searched to review recent estimates of the cost of illness associated 
with AF. METHODS: A systematic review was performed of Medline, EMBASE, 
Cochrane Library, HS Economic Evaluation, HTA and DARE databases, and confer-
ence abstracts, from 1990 to date. Total costs, direct and indirect costs were extracted. 
Inclusion criteria were AF or atrial ﬂutter patients. This included: persistent, perma-
nent and paroxysmal AF. Exclusion criteria were acute onset AF and Post operative 
AF. RESULTS: A total of 875 records were retrieved and 34 studies were included. 
The burden of AF is high and is increasing over time. Direct cost estimates ranged 
from $2,000 to $12,000 per patient per year in the USA, and from a400 to a3,000 
in Western Europe. This is high or equivalent compared to estimates for other chronic 
conditions as diabetes (CAD$306; Canada 1999) and chronic angina (US$4949; USA 
1999). The direct cost of managing AF represented 0.9%–2.4% of the national health 
care budget for the UK (2000) and had approximately doubled over the previous 5 
years. Inpatient care and interventional procedures represented the largest cost com-
ponent (where reported), accounting for 50% to 70% of total costs. In the USA, AF 
hospitalisations alone cost an estimated $6.65 billion per annum (2005). If indirect 
costs were included, cost estimates increased by up to 20% over direct costs alone. 
CONCLUSIONS: The economic burden of AF is high in comparison to other chronic 
conditions, and is expected to increase over time due to population ageing; hospitalisa-
tions represent the main cost driver.
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OBJECTIVES: Assess clinical management and associated economic burden over a 
12-month period following the acute phase of ischemic stroke in French primary care 
patients. METHODS: A questionnaire covering the course of patient management 
from initial diagnosis through one year of follow up was sent to 100 general practi-
tioners from 4 representative regions of France. Each GP was asked to complete a 
questionnaire for 2 patients with IS between April 1, 2005 and March 31, 2006 using 
one-year data recorded from their own ﬁles. RESULTS: The sample size consisted of 
196 patients, almost all of whom were hospitalized. Mean hospital LOS was 23 days. 
The ﬁrst service most patients (81.3%) were admitted to was the emergency unit. All 
had imaging tests (96.8%). With the exception of specialised stroke units, severity or 
dependency scales were infrequently administered upon arrival. At discharge, 55% of 
patients went home and 25% went to rehabilitation centres. During the 12-month’s 
following IS, rehospitalisation for reasons relating to stroke was observed in 16% of 
patients. One year after discharge, per patient costs of IS amounted to a18,459 
(15,762–21,157), with the acute phase accounting for 41%, rehabilitation 30% and 
ambulatory care 15%. Drug costs were the least expensive element of IS (2% of total 
cost). CONCLUSIONS: Results observed were consistent with previously published 
data. Higher mean length of stay seen in the present study may be explained by the 
averaging of geriatric and re-education unit LOS (32 and 62 days, respectively) versus 
12 days in specialized stroke units. The present study conﬁrmed that most patients 
are not cared for in specialized stroke units despite acknowledgement that such units 
offer improved management (better assessment, lower LOS). Costs incurred during 
the year following IS were mainly due to disability after the acute phase. Medication 
cost was not signiﬁcant.
PCV71
PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN 
PATIENTS WITH METABOLIC SYNDROME IN SPAIN: AN 
EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL
Alegría E1, Piñol C2, Langham S3, Stevens W4, Jeffries D5
1Clinica Universitaria de Navarra, Pamplona, Navarra, Spain, 2Bayer HealthCare, Barcelona, 
Spain, 3Independent Consultant, Manchester, UK, 4Independent Consultant, Boston, MA, 
USA, 5MRC Tropical Disease Research Unit, Banjul, Gambia
OBJECTIVES: To assess the current (2008) and future (2020) prevalence and cost of 
illness of hypertension (HT) in patients with metabolic syndrome (MetS) and the 
impact on cost-of illness under different potential treatment patterns. METHODS: An 
age, sex and risk group structured prevalence based cost-of-illness model was devel-
oped. Risk groups were HT patients with or without MetS. Published information on 
prevalence, incidence of cardiovascular events (CVE), prevalence of type 2 diabetes 
(DM2), treatment patterns and cost of management in patients with HT and MetS in 
Spain was used for 2008 and 2020. The direct medical costs of treatment of HT and 
associated sequelae are presented in 2008 Euros. RESULTS: The prevalence of HT 
with MetS in Spain was 11% in 2008 and 22% in 2020. The prevalence of MetS HT 
patients was 23% in 2008 and 45% in 2020. Prevalence increased markedly with age. 
The incidence of CVE per 1000 subjects was two times higher among HT patients 
with MetS (25% with vs. 13% without) and prevalence of DM2 per 100 subjects was 
ﬁve times higher among HT patients with MetS (28% with vs. 5% without). The 
cost-of-illness of HT, including the cost associated with treating CVE and DM2, was 
a4600 million in 2008 and a8,200 million in 2020. Those with MetS made up 42% 
and 65% of this cost. An increased use of newer antihypertensives resulted in a reduc-
tion in CVE and cases of new onset diabetes. CONCLUSIONS: HT patients with 
MetS currently make up around a quarter of the HT population in Spain but account 
for nearly half of the costs. Costs will increase in the future due to an aging population 
and an increase in the prevalence of MetS. The choice of antihypertensive treatment 
for this high risk patient population has become an important consideration with the 
newer antihypertensives demonstrating better adherence reducing the risk of CV 
disease and reduced risk of treatment-related new onset diabetes.
